MYCHELANGELO Trademark

Trademark Overview


On Wednesday, June 1, 2022, a trademark application was filed for MYCHELANGELO with the United States Patent and Trademark Office. The USPTO has given the MYCHELANGELO trademark a serial number of 97438108. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, May 28, 2024. This trademark is owned by Omega Therapeutics, Inc.. The MYCHELANGELO trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical agents affecting DNA structure by targeting DNA structure to treat various diseases in the nature of monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease; therapeutic pharmaceutical agents containing MYC inhibiting properties for the treatment of monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease

Scientific research; pharmaceutical research services; medical research; technical scientific consulting services in the field of biotechnology; product development for others in the field of biotechnology; development of pharmaceutical preparations and medicines; research and development in the field of computational biology, bioinformatics, biotechnology and pharmaceuticals

General Information


Serial Number97438108
Word MarkMYCHELANGELO
Filing DateWednesday, June 1, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, May 28, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 4, 2023

Trademark Statements


Goods and ServicesPharmaceutical agents affecting DNA structure by targeting DNA structure to treat various diseases in the nature of monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease; therapeutic pharmaceutical agents containing MYC inhibiting properties for the treatment of monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease
Goods and ServicesScientific research; pharmaceutical research services; medical research; technical scientific consulting services in the field of biotechnology; product development for others in the field of biotechnology; development of pharmaceutical preparations and medicines; research and development in the field of computational biology, bioinformatics, biotechnology and pharmaceuticals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 9, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, February 24, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOmega Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02141

Party NameOmega Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Trademark Events


Event DateEvent Description
Wednesday, January 18, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 9, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, January 9, 2023ASSIGNED TO EXAMINER
Wednesday, January 18, 2023NON-FINAL ACTION WRITTEN
Wednesday, January 18, 2023NON-FINAL ACTION E-MAILED
Thursday, February 23, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, February 23, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 24, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 28, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 4, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 4, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 30, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, June 1, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, June 1, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, June 1, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 22, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 22, 2023SOU EXTENSION 1 FILED
Wednesday, November 22, 2023SOU EXTENSION 1 GRANTED
Friday, November 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 28, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, May 28, 2024SOU EXTENSION 2 FILED
Tuesday, November 26, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, May 29, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 28, 2024SOU EXTENSION 2 GRANTED